1. INTRODUCTION
===============

Brain metastases are a cause of significant morbidity. An estimated 20%--40% of cancer patients will develop brain metastases during their illness [@b1-co15-5-226e25]. The most common primary cancers that metastasize to the brain are lung, breast, and gastrointestinal cancers [@b2-co15-5-226e25],[@b3-co15-5-226e25]. Depending on the location of the brain metastases, patients may suffer from neurologic symptoms that include headaches, focal weakness, mental disturbances, behavioural changes, seizures, speech difficulty, and ataxia [@b4-co15-5-226e25]. The prognosis for patients with brain metastases is generally poor; median survival is 1 month for patients not receiving treatment. Use of corticosteroids to reduce cerebral edema has been associated with symptom improvement [@b2-co15-5-226e25].

Whole-brain radiotherapy ([wbrt]{.smallcaps}) is the standard treatment for brain metastases. About 30%--40% of affected patients present with a single brain metastasis, but most present with multiple lesions [@b5-co15-5-226e25]. The objective of [wbrt]{.smallcaps} is to provide symptomatic relief, to allow for tapering of the dose of corticosteroids, and to possibly improve survival. Although many trials have shown that [wbrt]{.smallcaps} can reduce neurologic symptoms, median survival following a diagnosis of brain metastases is generally only 3--6 months [@b6-co15-5-226e25]. Patients with a solitary brain metastasis, good performance status, and controlled extracranial disease may be considered for more aggressive treatment such as surgery with postoperative radiotherapy or stereotactic radiosurgery. Radiosensitizers, chemotherapy, and various radiotherapy dose fractionation schedules have also been explored to improve the outcome of brain metastases [@b7-co15-5-226e25]--[@b11-co15-5-226e25].

The World Health Organization ([who]{.smallcaps}) describes health as a "state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity" [@b12-co15-5-226e25]. This subjective, multidimensional definition of health encourages health care professionals to focus not only on a patient's length of life, but also his or her quality of life ([qol]{.smallcaps}). Quality of life can be seen as a balance between minimizing treatment risks and maximizing benefits, including physical and psychological effects [@b13-co15-5-226e25]. Because patients with brain metastases have limited survival, treatment options that are less morbid and that maximize [qol]{.smallcaps} are essential.

An Outcomes Working Group was formed by the Health Services Research Committee in the American Society of Clinical Oncology to define the outcomes of cancer treatment that should be considered for assessment and cancer treatment guidelines. Quality of life was rated as an endpoint secondary in importance only to survival. The group suggested that these two patient outcomes---survival and [qol]{.smallcaps}---should take precedence over cancer outcomes such as response rate[@b14-co15-5-226e25]. The importance of including [qol]{.smallcaps} as a component of treatment assessment was also emphasized by Tannock, who wrote, "When cure is elusive, it is time to start treating the patient and not the tumor" [@b15-co15-5-226e25].

Previous clinical trials have defined the efficacy of treatment using some of the following endpoints: survival, response, radiologic or imaging response, observer-rated neurologic symptoms, time to recurrence of intracranial disease, cause of death, and preservation of the ability to function independently [@b16-co15-5-226e25]--[@b21-co15-5-226e25]. However, few studies have focused on [qol]{.smallcaps} and improvement in patient-rated symptoms as primary outcomes.

To accurately measure the extent to which previous trials utilized [qol]{.smallcaps} tools to evaluate the efficacy of radiotherapy for treatment of brain metastases, we undertook a literature review to examine the common endpoints and [qol]{.smallcaps} instruments used.

A preponderance of the published trials used a performance status scale such as the Karnofsky performance status ([kps]{.smallcaps}) to quantify the general well-being of patients with brain metastases [@b19-co15-5-226e25],[@b22-co15-5-226e25]--[@b25-co15-5-226e25]. The purpose of a performance status assessment is to quantify a patient's level of function, level of ambulation, and ability for self-care[@b26-co15-5-226e25] The [kps]{.smallcaps} is rated in increments of 10 on a scale of 0 to 100, with 100 meaning "normal, no complaints, no signs of disease" and 0 meaning "death". A score is assigned based on assessment by an observer such as a physician, nurse, or researcher [@b27-co15-5-226e25]. Trials often use a performance score to describe their study population or as a component of the study's exclusion criteria---for example, patients below a certain [kps]{.smallcaps} score are deemed ineligible [@b28-co15-5-226e25],[@b29-co15-5-226e25].

Although performance status is one of the dimensions of [qol]{.smallcaps}, [qol]{.smallcaps} is subjective and should reflect how a patient feels [@b30-co15-5-226e25]. The [kps]{.smallcaps} was evaluated previously, and although it was found to be a reliable instrument, it did not capture the overall concept of [qol]{.smallcaps} [@b31-co15-5-226e25]--[@b33-co15-5-226e25]. In the present study, only patient-rated instruments that strive to assess all dimensions of [qol]{.smallcaps} were deemed to be [qol]{.smallcaps} instruments; observer-rated performance instruments such as the [kps]{.smallcaps} were deemed to be performance scales.

2. METHODS
==========

2.1 Search Strategy
-------------------

We conducted a systematic search of the [medline]{.smallcaps} (1950 to December 2007) and Cochrane Central Register of Controlled Trials (4th quarter 2007) databases. The terms "brain neoplasms" and "brain metastas\#s" were used. The subheading "secondary" was selected to narrow the search to metastases to the brain (so as to exclude primary brain cancer). That search was combined with the terms "radiotherapy" or "quality of life." Relevant articles and abstracts were reviewed, and the reference lists from these sources were manually searched for additional relevant trials. The search was not limited by year of publication.

2.2 Inclusion Criteria
----------------------

Articles were included in the literature review if they met these criteria:

-   **Population** Studies of adult participants who had been diagnosed with one or more brain metastases by computed tomography or magnetic resonance imaging.

-   **Intervention** [wbrt]{.smallcaps} in one study arm.

-   **Type of study** Randomized or quasi-randomized trials and prospective or retrospective cohort studies.

-   **Outcomes** Survival, [qol]{.smallcaps}, symptom control, neurologic function, toxicity, response of brain metastases to treatment, cause of death, duration of functional independence, and intracranial progression-free duration.

2.2 Exclusion Criteria
----------------------

Articles were excluded from the literature review if they were

-   individual case reports or review articles

-   published in languages other than English, or

-   phase [i]{.smallcaps} and [ii]{.smallcaps} trials for which phase [iii]{.smallcaps} trials were already available.

2.3 Data Extraction
-------------------

The following information extracted from the studies:

-   Number of patients accrued and evaluated in each study arm

-   Patient inclusion and exclusion criteria for studies that included chemotherapy, surgery, or radiosurgery in one study arm

-   Treatment details such as chemotherapy drugs or radiosensitizer

-   Total dose and fractionation schedule for [wbrt]{.smallcaps} trials

-   Outcomes such as median survival, overall survival, neurologic function, 1-year local control, and overall response

-   Use of [qol]{.smallcaps} instruments, performance status scales, and neurologic function assessments

-   Other assessment tools, if used

3. RESULTS
==========

We identified sixty-one trials that treated patients using [wbrt]{.smallcaps} in at least one study arm.

3.1 Single Brain Metastasis
---------------------------

Nine of the sixty-one studies evaluated treatment of patients with a solitary brain metastasis. Two published trials and one abstract examined the role of surgery and [wbrt]{.smallcaps} as compared with [wbrt]{.smallcaps} alone [@b23-co15-5-226e25],[@b29-co15-5-226e25],[@b34-co15-5-226e25]. One trial assessed the effectiveness of surgery and [wbrt]{.smallcaps} as compared with surgery alone [@b19-co15-5-226e25]. Epstein *et al.*[@b35-co15-5-226e25] compared survival outcomes of various dose escalation schedules. One multi-institutional retrospective study investigated the use of radiosurgery and [wbrt]{.smallcaps} [@b36-co15-5-226e25]. A study by Jyothirmayi *et al.* [@b37-co15-5-226e25] examined the efficacy of radiosurgery at diagnosis, radiosurgery and [wbrt]{.smallcaps} at diagnosis, and radiosurgery at recurrence. Another study compared the outcomes of radiosurgery alone, [wbrt]{.smallcaps} alone, and radiosurgery with [wbrt]{.smallcaps} [@b38-co15-5-226e25] Roos *et al.* [@b39-co15-5-226e25] investigated the results of randomizing patients to [wbrt]{.smallcaps} or observation after the patients had been treated with surgery or radiosurgery. Their study also examined the [qol]{.smallcaps} of the study population.

3.2 Multiple Brain Metastases
-----------------------------

We identified fifty-two studies involving treatment of multiple brain metastases. One trial examined the use of corticosteroids and [wbrt]{.smallcaps} as compared with [wbrt]{.smallcaps} alone [@b40-co15-5-226e25]. In another trial, all patients received dexamethasone before [wbrt]{.smallcaps}, after which they were randomized to [wbrt]{.smallcaps} with a dose of dexamethasone or to [wbrt]{.smallcaps} alone [@b41-co15-5-226e25]. Two retrospective trials examined the outcomes of multiple treatments including [wbrt]{.smallcaps}, surgery, chemotherapy, or supportive care [@b42-co15-5-226e25],[@b43-co15-5-226e25]. Twelve studies examined the use of various [wbrt]{.smallcaps} dose fractionation schedules [@b6-co15-5-226e25],[@b10-co15-5-226e25],[@b22-co15-5-226e25],[@b28-co15-5-226e25],[@b44-co15-5-226e25]--[@b51-co15-5-226e25], and seven trials assessed the efficacy of radiosensitizers and [wbrt]{.smallcaps} as compared with [wbrt]{.smallcaps} alone [@b9-co15-5-226e25],[@b21-co15-5-226e25],[@b24-co15-5-226e25],[@b25-co15-5-226e25],[@b52-co15-5-226e25]--[@b54-co15-5-226e25]. Chemotherapy and [wbrt]{.smallcaps} were compared in eight studies [@b7-co15-5-226e25],[@b8-co15-5-226e25],[@b55-co15-5-226e25]--[@b60-co15-5-226e25]. Five trials examined the efficacy of whole-brain re-irradiation in patients with brain metastases [@b61-co15-5-226e25]--[@b65-co15-5-226e25]. One study randomized patients with 1--3 brain metastases to [wbrt]{.smallcaps} or [wbrt]{.smallcaps} followed by stereotactic radiosurgery boost [@b18-co15-5-226e25]. One retrospective study examined the outcomes of [wbrt]{.smallcaps} or Gamma Knife radiosurgery [@b66-co15-5-226e25]. One randomized trial examined the combination of [wbrt]{.smallcaps} and radiosurgery as compared with [wbrt]{.smallcaps} alone for patients with 2--4 brain metastases [@b20-co15-5-226e25]. Three other studies looked at [wbrt]{.smallcaps} and radiosurgery as compared with radiosurgery alone for patients with 1--3 brain metastases [@b67-co15-5-226e25], 1--4 brain metastases [@b68-co15-5-226e25], and single or multiple brain metastases [@b69-co15-5-226e25]. One study focused on [qol]{.smallcaps} and the patients' perspectives regarding management-related complications in addition to the radiosurgery [@b68-co15-5-226e25]. Another study investigated the survival and [qol]{.smallcaps} of patients who were randomized to [wbrt]{.smallcaps} with efaproxiral or to [wbrt]{.smallcaps} alone[@b70-co15-5-226e25]. Six other studies examined the role of [qol]{.smallcaps} or patient-rated symptoms when assessing the effectiveness of [wbrt]{.smallcaps} [@b17-co15-5-226e25],[@b71-co15-5-226e25]--[@b75-co15-5-226e25]. Two studies assessed the neurocognitive function ([ncf]{.smallcaps}) of patients who had been treated with [wbrt]{.smallcaps} and a radiosensitizer [@b76-co15-5-226e25] or with [wbrt]{.smallcaps} alone [@b27-co15-5-226e25]. Lastly, one study investigated both [ncf]{.smallcaps} and [qol]{.smallcaps} of patients treated with [wbrt]{.smallcaps} [@b77-co15-5-226e25].

3.3 Study Outcomes
------------------

[Tables I](#tI-co15-5-226e25){ref-type="table"}--[IX](#tIX-co15-5-226e25){ref-type="table"} present the outcomes of the trials outlined in the previous subsection. The endpoints of overall median survival, overall survival at 6 months, 1-year local control, overall response rate, [qol]{.smallcaps}, neurologic function, and symptom control are reported when available. The number of [qol]{.smallcaps} instruments used in each study is also recorded.

3.4 QOL Instruments
-------------------

A total of 24 different [qol]{.smallcaps} instruments, including performance scales, study-designed performance instruments, validated [qol]{.smallcaps} instruments, study-designed [qol]{.smallcaps} assessments, neurologic function scales, study-designed neurologic instruments, and [ncf]{.smallcaps} tests were used in the trials ([Tables X](#tX-co15-5-226e25){ref-type="table"}--[XIV](#tXIV-co15-5-226e25){ref-type="table"}). Six studies did not use any [qol]{.smallcaps} measures [@b20-co15-5-226e25],[@b43-co15-5-226e25],[@b60-co15-5-226e25]--[@b62-co15-5-226e25],[@b78-co15-5-226e25]. The most commonly used instruments were the [kps]{.smallcaps} scale (*n* = 33) and various forms of neurologic function classification (*n* = 21). The number of [qol]{.smallcaps} instruments used in each study varied from 0 to 8, but most of the studies used 1 (*n* = 26, 43%) or 2 (*n* = 21, 34%) instruments. Of the 23 different instruments used, 8 (35%) assessed [qol]{.smallcaps}, 7 (30%) assessed [ncf]{.smallcaps}, 5 (22%) assessed performance status, and 3 (13%) assessed neurologic function.

Of the 8 [qol]{.smallcaps} instruments used, 2 were study-designed assessments [@b68-co15-5-226e25],[@b74-co15-5-226e25]. Kondziolka *et al.* [@b68-co15-5-226e25] designed a 10-item survey to ask patients treated with [wbrt]{.smallcaps} and radiosurgery or with radiosurgery alone about their treatment perceptions, side effects (hair loss, fatigue, memory, mood or affect, intellectual concentration, employment), activity level, and overall satisfaction. This survey was used in a patient population in which 90% of the patients had a [kps]{.smallcaps} status of 90 or 100. After [wbrt]{.smallcaps}, the side effects reported were alopecia (88%); excess fatigue (85%); problems with short-term memory (72%), long-term memory (33%), and concentration (61%); and depression (54%). Also, patients more frequently reported short-term memory problems (*p* \< 0.0001), long-term memory problems (*p* = 0.03), and concentration problems (*p* = 0.0007) when they had undergone both [wbrt]{.smallcaps} and radiosurgery as compared with radiosurgery alone. More patients considered radiosurgery a good treatment for them as compared with [wbrt]{.smallcaps} (76% vs. 56%, *p* = 0.25) [@b68-co15-5-226e25]

Sehlen *et al.* [@b74-co15-5-226e25] developed the Current Situation in Personal Life questionnaire because previous trials had indicated that psychological and sociodemographic variables could influence survival in cancer patients [@b74-co15-5-226e25]. These authors assessed patients ([kps]{.smallcaps} \> 70) who had undergone [wbrt]{.smallcaps} for primary central nervous system tumours or brain metastases; their instrument was designed to assess important sociodemographic variables and factors in the patients' personal lives, such as marital status, number of children or people in the household, level of education, employment, family history of cancer, symptoms, relationships with family and friends, social life, hobbies, religion, and significant events. Interestingly, the results showed that "living with a spouse" had a statistically significant positive influence on survival (*p* = 0.033) [@b74-co15-5-226e25].

Addeo *et al.* [@b55-co15-5-226e25], Bezjak *et al.* [@b71-co15-5-226e25], and Sehlen *et al.*[@b74-co15-5-226e25] used the Functional Assessment of Cancer Therapy---General scale ([fact]{.smallcaps}-[g]{.smallcaps}). This questionnaire is a validated instrument that evaluates the [qol]{.smallcaps} of cancer patients in 5 domains, including physical well-being (7 items), social or family well-being (7 items), relationship with the physician (2 items), emotional well-being (5 items), and functional well-being (7 items) [@b79-co15-5-226e25]. Sehlen and her colleagues showed that the overall [fact]{.smallcaps}-[g]{.smallcaps} score had a significant influence on survival (*p* = 0.003) [@b74-co15-5-226e25].

The [fact]{.smallcaps}-[g]{.smallcaps} is often supplemented by site-specific questionnaires such as the [fact]{.smallcaps}--Brain subscale ([fact-- br]{.smallcaps}) as used by Bezjak *et al.* [@b71-co15-5-226e25] and Addeo *et al.* [@b55-co15-5-226e25] The [fact]{.smallcaps}-[br]{.smallcaps} subscale contains 19 additional items pertaining to patients with brain metastases specifically, including symptoms, self-care, cognitive ability, and ease in usual activities [@b79-co15-5-226e25]. Bezjak *et al.* [@b71-co15-5-226e25] found that, as compared with baseline, 8 of 23 patients showed improvement and 15 patients showed deterioration in assessed [qol]{.smallcaps} using the [fact]{.smallcaps}-[g]{.smallcaps} and [fact]{.smallcaps}-[br]{.smallcaps} questionnaires 1 month after palliative radiotherapy.

The full [fact]{.smallcaps}-[br]{.smallcaps} scale contains 53 questions (as compared with the subscale, with its 19 questions). Addeo *et al.*[@b55-co15-5-226e25] used the [fact g]{.smallcaps} and selected 26 items from the [fact]{.smallcaps}-[br]{.smallcaps} scale to assess [qol]{.smallcaps} in patients who underwent [wbrt]{.smallcaps} and temozolomide treatment. A significant improvement in [qol]{.smallcaps} was seen with the [fact]{.smallcaps}-[g]{.smallcaps} questionnaire (*p* \< 0.0001). At baseline, 51% of patients reported, positively, that they were "quite a bit" or "very much" content with the quality of their life; 49% reported, negatively, that they were "not at all" or "a little bit" content with the quality of their life. Three months after treatment, 79% were content with their [qol]{.smallcaps}, and 21% were not content.

Gerrard *et al.* [@b72-co15-5-226e25], Yaneva *et al.* [@b75-co15-5-226e25], and Roos *et al.*[@b39-co15-5-226e25] used the European Organization for Research and Treatment of Cancer ([eortc]{.smallcaps}) Core Quality of Life Questionnaire ([qlq]{.smallcaps}-C30). This general questionnaire consists of 5 domains assessing functioning (physical, role, cognitive, emotional, and social), 1 domain assessing global [qol]{.smallcaps}, 3 domains assessing common symptoms (fatigue, pain, nausea or vomiting), 5 single items assessing other symptoms (dyspnea, insomnia, anorexia, constipation, and diarrhea), and 1 item assessing financial impact.

Yaneva *et al.* [@b75-co15-5-226e25] evaluated the [qol]{.smallcaps} of patients with a [kps]{.smallcaps} greater than 70 before and after [wbrt]{.smallcaps} treatment. A significant improvement was evident after radiotherapy in all domains of functioning and in all symptoms with the exception of dyspnea, diarrhea, and financial difficulties. A significant improvement in health-related [qol]{.smallcaps} was also reported (*p* \< 0.0001).

Gerrard *et al.* [@b72-co15-5-226e25] and Roos *et al.* [@b39-co15-5-226e25] used the supplementary Brain Cancer Module ([bcm]{.smallcaps}) in addition to the [eortc qlq]{.smallcaps}-C30. However, the [bcm]{.smallcaps} was designed for patients with primary brain tumour. It consists of 20 questions that assess side effects of treatment, outlook for the future, and common symptoms [@b80-co15-5-226e25]. Validation of this instrument in patients with brain metastases has not been reported.

When using the [eortc qlq]{.smallcaps}-C30 and [bcm]{.smallcaps}, Gerrard *et al.* [@b72-co15-5-226e25] experienced difficulties with data collection and found that the questionnaires were lengthy and demanding, particularly for their poor-prognosis group. From the 18 patients analyzed in their first study, high levels of fatigue and drowsiness were seen throughout the study period (baseline to 8 weeks) and only 1 patient and 2 patients improved in [qol]{.smallcaps} at 2 weeks and 4 weeks respectively. Their second study, which also used the [eortc qlc]{.smallcaps}-30 and [bcm]{.smallcaps} 20, was terminated prematurely because of difficulties with data collection. Improvement in [qol]{.smallcaps} was not evident in any of the 6 patients accrued. Subsequently, in a third study, these authors simplified their [qol]{.smallcaps} assessment by asking only the global health score and global [qol]{.smallcaps} items of the questionnaire. Of 14 patients, 7 experienced transient improvements at some stage following [wbrt]{.smallcaps}.

Similarly, the randomized study of [wbrt]{.smallcaps} or control group post surgery or post radiosurgery by Roos *et al.* [@b39-co15-5-226e25] was also terminated prematurely because of its slow accrual. As a result of the small sample size (*n* = 19), the investigators did not conduct a detailed [qol]{.smallcaps} analysis. They found that the differences in the global health scores and global [qol]{.smallcaps} scores between the two study arms were nonsignificant at 2 months (*p* = 0.94) and at 5 months (*p* = 0.50). The investigators concluded that their study did not indicate that [wbrt]{.smallcaps} caused deterioration in overall health or overall [qol]{.smallcaps}.

Chow *et al.* [@b17-co15-5-226e25] used the Edmonton Symptom Assessment System ([esas]{.smallcaps}) in their study of patient-rated symptoms in patients with brain metastases treated with [wbrt]{.smallcaps}. The [esas]{.smallcaps} is a validated instrument designed for patients receiving palliative care. It evaluates 9 symptoms, including global pain, nausea, anxiety, depression, tiredness, drowsiness, sense of well-being, appetite, and shortness of breath. Each symptom is rated on a scale from 0 to 10, where 0 represents absence of the symptom and 10 represents the worst possible symptom. The [esas]{.smallcaps} has been shown to be a quick tool to use and to predominantly reflect the physical well-being of the patient [@b81-co15-5-226e25]. In the study by Chow and colleagues, 19%, 20%, and 15% of the patients died during the first, second, and third month following [wbrt]{.smallcaps}. The study population had statistically significant deterioration in the mean differences between their 1-year follow-up and baseline scores for fatigue (1.0 to 1.8), drowsiness (1.2 to 1.8), and appetite (2.2 to 2.4).

Mintz *et al.* [@b29-co15-5-226e25] and Scott *et al.* [@b70-co15-5-226e25] used the Spitzer Quality of Life index (Spitzer Q-L index). This validated instrument is composed of 5 domains: general activity, daily living, health, support, and outlook. Each domain is rated from 0 to 2 and each score is accompanied by verbal descriptions. For example, for the health domain, the patient could report either feeling well or "great" most of the time (score 2), lacking in energy or being not entirely "up to par" occasionally (score 1), or feeling very ill or "lousy," weak and washed out for most of the week (score 0) [@b82-co15-5-226e25].

Mintz *et al.* [@b29-co15-5-226e25] conducted a controlled trial in which patients with a single brain metastasis were randomized to either [wbrt]{.smallcaps} and surgery or to [wbrt]{.smallcaps} alone. When comparing the two study arms, the mean [qol]{.smallcaps} scores were not significantly different at either of the study periods analyzed (1--3 months and 4--6 months).

Scott *et al.*[@b70-co15-5-226e25] assessed the [qol]{.smallcaps} of patients randomized to [wbrt]{.smallcaps} with efaproxiral or to [wbrt]{.smallcaps} alone. At the 6-month follow-up as compared with baseline, patients in the [wbrt]{.smallcaps} and efaproxiral arm had higher Spitzer Q-L scores than did the patients in the [wbrt]{.smallcaps} arm (*p* = 0.019). The authors also indicated that a score of 7 or better out of 10 before treatment was a significant predictor of overall survival. Patients with a score of 7 or better experienced a 48% reduction in death rate (*p* = 0.0079).

Regine *et al.* [@b77-co15-5-226e25] used the Profile of Mood States--Short Form ([poms]{.smallcaps}-[sf]{.smallcaps}), a 30-item questionnaire organized into 6 mood scales: tension--anxiety, depression--dejection, anger--hostility, vigour--activity, fatigue--inertia, and confusion--bewilderment. The individual scales are combined to achieve an indicator of overall mood. A higher mood disturbance score indicates greater mood disturbance [@b77-co15-5-226e25]. Although compliance rates for completion of the [poms]{.smallcaps}-[sf]{.smallcaps} was high before treatment (95% or more), at treatment completion (84% or more), and at 1 month after treatment (70% or more), the results of the questionnaire were not reported because patient mood was not the primary objective of the study [@b77-co15-5-226e25].

3.5 Performance Evaluation
--------------------------

The [kps]{.smallcaps} (discussed earlier) was the tool most commonly used to assess performance status in thirty-three studies. Results from Patchell *et al.* [@b34-co15-5-226e25] are highlighted, because these authors used the [kps]{.smallcaps} as a measurement of [qol]{.smallcaps} when comparing patients with a single brain metastasis who had undergone either surgery and [wbrt]{.smallcaps} or [wbrt]{.smallcaps} alone. The length of time that [kps]{.smallcaps} scores remained at 70 or better was used as a determinant of [qol]{.smallcaps}. Patients in the surgery and [wbrt]{.smallcaps} arm maintained [kps]{.smallcaps} scores of 70 or better for much longer than did patients who received radiation alone (38 weeks vs. 8 weeks, *p* \< 0.005). In a prospective study, Li *et al.* [@b38-co15-5-226e25] compared the outcomes of 3 treatment arms in patients with a single brain metastasis and a [kps]{.smallcaps} score of 60 or better. An increase in [kps]{.smallcaps} score was seen in all 3 treatment arms: 88.9% (*n* = 16), 87.0% (*n* = 20), and 48.3% (*n* = 14) in patients who underwent radiosurgery in combination with [wbrt]{.smallcaps}, radiosurgery alone, and [wbrt]{.smallcaps} alone respectively. A greater improvement in [kps]{.smallcaps} was seen in patients treated with radiosurgery alone or with radiosurgery in combination with [wbrt]{.smallcaps}.

A study by Rosenman *et al.* [@b63-co15-5-226e25] found that elective radiation could improve the [qol]{.smallcaps} of patients with small-cell lung carcinoma, although it did not increase the patients' survival. All patients initially received a standard course of [wbrt]{.smallcaps}. After that course of treatment, 28 patients received elective radiation, and 24 patients received radiation only when brain metastases occurred ("therapeutic radiation"). A [kps]{.smallcaps} score above 60 was used by the investigators as a measure of [qol]{.smallcaps}. Patients in the electively radiated arm maintained a [kps]{.smallcaps} score greater than 60 for a mean time of 10 months as compared with a mean time of 6 months for patients in the therapeutically radiated arm.

The Eastern Cooperative Oncology Group ([ecog]{.smallcaps}) evaluation was used in eleven of the studies to determine performance status. Unlike the [kps]{.smallcaps}, which ranges from 0 to 100, the [ecog]{.smallcaps} is simpler. It ranges from 0 to 4, where 0 stands for "normal activity" and 4 means "unable to get out of bed." Roos *et al.* [@b39-co15-5-226e25] used [ecog]{.smallcaps} as a part of their [qol]{.smallcaps} assessment (baseline vs. first follow-up) when comparing patients randomized to [wbrt]{.smallcaps} or to observation after surgery or radiosurgery. No significant difference was found between the two study arms (*p* = 0.80).

Five of the studies used the General Performance Status ([gps]{.smallcaps}), which ranges from 1, which means "normal," to 5, which means "100% bedridden." Also, two of the studies used the Barthel index of activity of daily living, which is a validated measure for patients with neurologic disability. Its questions focus on physical performance in 10 areas: feeding, transfers from bed to chair and back, grooming, toilet use, bathing, mobility, climbing stairs, dressing, stool control, and bladder control.

Finally, four of the studies designed their own scales to evaluate performance status [@b22-co15-5-226e25],[@b23-co15-5-226e25],[@b40-co15-5-226e25],[@b50-co15-5-226e25]. For example, Horton *et al.* [@b40-co15-5-226e25] measured performance status using a scale from 0 ("normal performance") to 4 ("completely bedridden"). Kurtz *et al.* [@b50-co15-5-226e25] measured performance status on a scale from 0 to 100, where scores from 70 to 100 indicated ambulatory patients and scores under 70 indicated non-ambulatory patients. Harwood *et al.* [@b22-co15-5-226e25] classified the functional status of their patients by level [i]{.smallcaps}, [ii]{.smallcaps}, [iii]{.smallcaps}, and [iv]{.smallcaps}, where level [i]{.smallcaps} meant that the patient was "intellectually and physically able to work with neurological abnormalities minor or absent" and level [iv]{.smallcaps} meant the patient had "profound neurologic disability." Noordijk and colleagues assessed the general well-being of the patients by designing a functionally independent survival tool [@b23-co15-5-226e25]. Patients were considered to be functionally independent as long as their score on the [ecog]{.smallcaps} scale was 1 or lower (symptomatic, but almost completely independent) and their score on a version of a neurologic function classification was 1 or lower (patient can perform normal activities with minimal difficulties).

3.6 Evaluation of Neurologic Function and Symptoms
--------------------------------------------------

In 23 studies ([Table XIII](#tXIII-co15-5-226e25){ref-type="table"}), a measure of the neurologic function and symptoms of the patients was reported. Various versions of a neurologic functional classification or scale was used in 20 reports. Bezjak *et al.* [@b71-co15-5-226e25] modelled an assessment tool after symptom items included in the [fact]{.smallcaps}-[br]{.smallcaps} and the [bcm]{.smallcaps} 20. This patient-rated assessment tool consisted of 16 items specific to patients with brain metastases. Symptoms were subdivided into raised intracranial pressure (3 items), effects associated with steroid use (4 items), possible subacute side effects (4 items), and effects associated with brain metastases (5 items). Robinet *et al.* [@b7-co15-5-226e25] used the order classification to record the neurologic status of the patients.

3.7 Neurocognitive Function
---------------------------

Li *et al.* [@b76-co15-5-226e25], Murray *et al.* [@b27-co15-5-226e25], Regine *et al.* [@b77-co15-5-226e25], Roos *et al.* [@b39-co15-5-226e25], Scott *et al.* [@b70-co15-5-226e25], and Sehlen *et al.* [@b74-co15-5-226e25] assessed [ncf]{.smallcaps} in their studies, five of which included the Mini Mental Status Examination ([mmse]{.smallcaps}) as an instrument [@b27-co15-5-226e25],[@b39-co15-5-226e25],[@b70-co15-5-226e25],[@b74-co15-5-226e25],[@b77-co15-5-226e25] ([Table XIV](#tXIV-co15-5-226e25){ref-type="table"}). The [mmse]{.smallcaps} is a validated and easily administered tool consisting of 11 items designed to test cognitive function. It includes tests of the patient's knowledge of orientation (1 item); memory (2 items); immediate recall (1 item); attention, concentration, and calculation (1 item); and aphasia and apraxia (4 items) [@b27-co15-5-226e25] Roos *et al.*[@b39-co15-5-226e25] compared the [mmse]{.smallcaps} scores of patients with a single brain metastasis randomized to [wbrt]{.smallcaps} or to observation post surgery or post radiosurgery. Although the study was terminated prematurely because of slow accrual, no significant difference was found between the two study arms at the 12-month follow-up (*p* = 0.50).

The Hopkins Verbal Learning Test, which was used by Li *et al.* [@b76-co15-5-226e25] and Regine *et al.* [@b77-co15-5-226e25] is a memory test instrument and includes items for short- and long-term recall and word recognition [@b83-co15-5-226e25]. The Controlled Oral Word Association test used by Li *et al.* [@b76-co15-5-226e25] and Regine *et al.* [@b77-co15-5-226e25] assesses language and executive function skills where the patient's task is to produce, in 1 minute, as many words as possible beginning with a specific letter. Additionally, trials by Li *et al.* [@b76-co15-5-226e25] and Regine *et al.* [@b77-co15-5-226e25] used the trail-making test designed to test visual motor speed and executive function [@b83-co15-5-226e25].

Regine *et al.* [@b77-co15-5-226e25] included the Ruff 2 and 7 Test as a component of their [ncf]{.smallcaps} test battery to assess neglect, attention, and concentration. Li *et al.* [@b76-co15-5-226e25] assessed motor speed, visual--motor coordination, and single-hand dexterity with the Grooved Pegboard Test. Sehlen *et al.* [@b74-co15-5-226e25] used a modified abbreviated version of the Mini Mental State Inventory to evaluate mental capacity.

4. DISCUSSION
=============

In recent years, [qol]{.smallcaps} has become an increasingly important outcome in cancer trials. To date, fourteen trials on brain metastases that included an evaluation of the study population's [qol]{.smallcaps} have been published. Three of the trials used the [fact]{.smallcaps}-[g]{.smallcaps} and [fact]{.smallcaps}-[br]{.smallcaps} instruments, three used the [eortc qlq]{.smallcaps}-C30 and [bcm]{.smallcaps} 20 instruments, two designed [qol]{.smallcaps} instruments specifically for the trial, one used the [esas]{.smallcaps} instrument, two used the Spitzer Q-L index, and three used the [kps]{.smallcaps} as a tool to evaluate [qol]{.smallcaps}. Our findings suggest that, although numerous [qol]{.smallcaps} questionnaires exist, no standard questionnaire is currently used to assess [qol]{.smallcaps} in patients with brain metastases. Currently, the use of these different questionnaires does not allow for a comparison of [qol]{.smallcaps} across trials. A standard tool would be beneficial for comparisons across trials and for performing meta-analyses.

Our literature review shows that certain parameters of [qol]{.smallcaps} deteriorate after [wbrt]{.smallcaps} [@b17-co15-5-226e25],[@b71-co15-5-226e25],[@b72-co15-5-226e25]. Chow *et al.* [@b17-co15-5-226e25] concluded that the [esas]{.smallcaps} domains of fatigue, drowsiness, and appetite worsened after [wbrt]{.smallcaps} in their patients (baseline median [kps]{.smallcaps}: 60; range: 20--90). In the study by Gerrard *et al.* [@b72-co15-5-226e25], 10 of the 38 patients (26%; 95% confidence interval: 13%--43%) improved in at least one of the following parameters during the study period: [qol]{.smallcaps} score, Barthel index of activity of daily living, or [kps]{.smallcaps} 8 weeks after [wbrt]{.smallcaps}. However, 14 of 15 patients had deterioration in at least one of these parameters. Using the [fact]{.smallcaps}-[br]{.smallcaps} questionnaire, Bezjak *et al.*[@b71-co15-5-226e25] also found deterioration in [qol]{.smallcaps} from baseline to 1 month, but the difference was not statistically significant (*p* = 0.13). These findings have led authors to question whether patients with poor prognosis benefit from radiotherapy in terms of effect on [qol]{.smallcaps} and symptom experiences [@b17-co15-5-226e25],[@b72-co15-5-226e25].

For patients with a better prognosis, the results of Addeo *et al.* [@b55-co15-5-226e25], Yaneva *et al.* [@b75-co15-5-226e25], and Scott *et al.* [@b70-co15-5-226e25] showed that certain parameters of [qol]{.smallcaps} significantly improved after [wbrt]{.smallcaps} Addeo *et al.*[@b55-co15-5-226e25] used the [fact]{.smallcaps}-[g]{.smallcaps} and 26 of the [fact]{.smallcaps}-[br]{.smallcaps} scale items to assess [qol]{.smallcaps} in patients who underwent [wbrt]{.smallcaps} and temozolomide treatment. A significant improvement in [qol]{.smallcaps} was seen (*p* \< 0.0001). Three months after treatment, 79% were content with their quality of life, and 21% were discontent (compared with 51% positive respondents and 49% negative respondents at baseline).

Using a recursive partitioning analysis ([rpa]{.smallcaps}) based on the [kps]{.smallcaps}, the Radiation Therapy Oncology group established three prognostic classes for patients with brain metastases according to tumour, primary tumour status, presence of extracranial metastases, and age. Class [i]{.smallcaps} included patients with a [kps]{.smallcaps} of 70 or better, age below 65 years, no extracranial metastases, and a controlled primary tumour; these patients had a median survival of 7.1 months. In comparison, patients with a [kps]{.smallcaps} below 70 are class [iii]{.smallcaps} with a median survival of 2.3 months. All other patients belong to class [ii]{.smallcaps}, with a median survival of 4.2 months.

Addeo *et al.* [@b55-co15-5-226e25] included a high number of patients in the [rpa]{.smallcaps} classes [i]{.smallcaps} (*n* = 21, 36%) and [ii]{.smallcaps} (*n* = 22, 37%). That patient population differed greatly from the population included in the study by Bezjak *et al.* [@b71-co15-5-226e25], where 3, 31, and 41 patients were in [rpa]{.smallcaps} classes [i]{.smallcaps}, [ii]{.smallcaps}, and [iii]{.smallcaps} respectively.

Yaneva *et al* [@b75-co15-5-226e25] used the [eortc qlq]{.smallcaps}-C30 in a patient population who underwent [wbrt]{.smallcaps}. Significant improvements in functional indicators, symptoms, and health-related [qol]{.smallcaps} were found after [wbrt]{.smallcaps}. Those results differ from the findings of Gerrard *et al.* [@b72-co15-5-226e25], who also used the [eortc qlq]{.smallcaps}-C30 questionnaire; however, the population in their study satisfied at least two of the following criteria: [kps]{.smallcaps} below 70, more than 60 years of age, or a primary tumour site other than breast. In comparison, Yaneva *et al.* [@b75-co15-5-226e25] selected patients who had [kps]{.smallcaps} scores above 70.

Scott *et al.* [@b70-co15-5-226e25] randomized patients to [wbrt]{.smallcaps} with efaproxiral or to [wbrt]{.smallcaps} alone, using the Spitzer Q-L index as a measurement of [qol]{.smallcaps}. At the 6-month follow-up, patients who had received [wbrt]{.smallcaps} and efaproxiral had higher [qol]{.smallcaps} scores than did the patients who had received [wbrt]{.smallcaps} alone (*p* = 0.019). This study population also included patients with a better prognosis (only [rpa]{.smallcaps} class [i]{.smallcaps} and [ii]{.smallcaps} patients were included). Of the study population, 58% percent had a [kps]{.smallcaps} score of 90--100, and 42% had a [kps]{.smallcaps} score of 70--80.

One study found that certain parameters of [qol]{.smallcaps} did not deteriorate or improve after [wbrt]{.smallcaps}. Roos*et al.* [@b39-co15-5-226e25] randomized patients to [wbrt]{.smallcaps} or to no additional treatment post surgery or post radiotherapy. The [eortc]{.smallcaps} global health scores and global [qol]{.smallcaps} scores were not significant between the study arms at 2 months (*p* = 0.94) and at 5 months (*p* = 0.50). These patients also had a fairly good prognosis: solitary brain metastasis and 14, 4, and 1 of 19 patients in [rpa]{.smallcaps} classes [i]{.smallcaps}, [ii]{.smallcaps}, and [iii]{.smallcaps} respectively. Although no improvement in [qol]{.smallcaps} was evident, the results also did not indicate that [qol]{.smallcaps} deteriorated after patients received [wbrt]{.smallcaps}. Poor accrual and low statistical power likely contributed to this outcome.

The present review found that few [wbrt]{.smallcaps} studies included a measure of [qol]{.smallcaps} as a primary endpoint. A possible explanation is the difficulty in collecting data in a population of patients whose life expectancy is short. Patients with short survival and deterioration of health often contribute to high attrition rates in brain metastases [qol]{.smallcaps} studies [@b17-co15-5-226e25],[@b72-co15-5-226e25] For example, Bezjak *et al.*[@b71-co15-5-226e25] found that only 19% of patients had symptomatic improvement and that 55% had either progressed in their illness or had died at 1 month. Consequently, the drop-out bias affecting research studies must be kept in mind: patients included in the results are those able to complete follow-up assessments and are thus likely have a better prognosis than are the patients lost to follow-up [@b11-co15-5-226e25],[@b71-co15-5-226e25]. Scott *et al.* [@b70-co15-5-226e25] found that the Spitzer Q-L index was a better predictor of survival than the [kps]{.smallcaps} was, and they suggested the use of this [qol]{.smallcaps} instrument in predicting survival and assessing patient status. Sehlen and colleagues found that the overall [fact]{.smallcaps}-[g]{.smallcaps} score had a statistically significant correlation with survival (*p* = 0.003). Although data collection is a challenge in this study population, the results of Sehlen *et al.* [@b74-co15-5-226e25] suggest that [qol]{.smallcaps} is a worthwhile endpoint to include in future brain metastases trials and that it could possibly distinguish patients with a longer expected survival.

The studies identified in this review used 55 different performance status assessment tools and 23 different neurologic function instruments. However, these instruments were primarily used to categorize the patients into prognostic groups, to describe the study population, or to act as exclusion criteria. The study by Patchell *et al.* [@b34-co15-5-226e25] was an exception: the authors used the [kps]{.smallcaps} to evaluate the [qol]{.smallcaps} of patients before and after treatment. They determined [qol]{.smallcaps} by the length of time the [kps]{.smallcaps} remained at 70 or higher. Their results showed that the [kps]{.smallcaps} scores of patients in the combined radiotherapy and surgery arm were maintained for a much longer period than were the scores of patients who had undergone radiotherapy alone (38 weeks vs. 8 weeks, *p* \< 0.005) [@b34-co15-5-226e25]. Similarly, Li *et al.* [@b38-co15-5-226e25] compared [kps]{.smallcaps} scores from the day of treatment with scores from the first follow-up visit to determine if different treatments had an effect on the [qol]{.smallcaps} of lung cancer patients with a single brain metastasis. Improvements of 88.9% (*n* = 16) and 87.0% (*n* = 20) respectively were seen in the [kps]{.smallcaps} scores of patients who underwent radiosurgery in combination with [wbrt]{.smallcaps} and radiosurgery alone. In comparison, an improvement of 48.3% (*n* = 14) was seen in patients who underwent [wbrt]{.smallcaps} alone. A study by Rosenman *et al.*[@b63-co15-5-226e25] investigated whether [qol]{.smallcaps} improved with elective radiation after a standard course of [wbrt]{.smallcaps} in 28 patients (compared with 24 patients who received radiation therapeutically). These authors defined [qol]{.smallcaps} as the length of time a patient's [kps]{.smallcaps} score remained above 60. Patients in the electively radiated arm maintained a [kps]{.smallcaps} score above 60 for significantly longer than did the patients in the therapeutically radiated arm (10 months vs. 6 months).

The [ncf]{.smallcaps} is clearly an important concern for brain metastases patients. Although the [mmse]{.smallcaps} was the most frequently used measure of [ncf]{.smallcaps} in the studies, it is less sensitive to mild neurocognitive impairment and may not identify subtle improvements [@b68-co15-5-226e25],[@b83-co15-5-226e25]. In addition, the [mmse]{.smallcaps} has not been as thoroughly evaluated in patients with brain metastases as compared with patients with primary brain tumours [@b83-co15-5-226e25]. Hence, studies have designed [ncf]{.smallcaps} test batteries to thoroughly evaluate the [ncf]{.smallcaps} of study patients [@b77-co15-5-226e25],[@b83-co15-5-226e25]. Li *et al.* [@b76-co15-5-226e25] investigated the [ncf]{.smallcaps} of patients who had been treated with a radiosensitizer (gadolinium) and [wbrt]{.smallcaps}. Patients were classified as "good" or "poor" responders depending on whether their tumour reduction at 2 months was above or below the population median reduction of 45%. Their results showed that the "good" responders survived significantly longer than did the "poor" responders. Time to [ncf]{.smallcaps} deterioration was compared in the "good" and "poor" responders, and results indicated that patients with volume regression after radiation had a longer delay before [ncf]{.smallcaps} deterioration. The authors concluded that [ncf]{.smallcaps} and [qol]{.smallcaps} correlated in their study population and that efforts to prevent the worsening of [ncf]{.smallcaps} could help maintain [qol]{.smallcaps} [@b76-co15-5-226e25].

5. CONCLUSIONS
==============

Quality of life is an important outcome in the treatment of patients diagnosed with brain metastases. However, few clinical trials have focused on [qol]{.smallcaps} as a primary outcome. Common outcomes measured are survival, response to treatment, symptomatic relief, toxicity, and duration of independent function. The present review finds that various management methods for brain metastases have been explored, and yet median survival in this patient population has not improved significantly. Thus, less-morbid treatment options that preserve or improve [qol]{.smallcaps} in these patients are important.

Our literature review found that a number of [qol]{.smallcaps} instruments have been used to evaluate patients with brain metastases. Additional assessment tools, including performance status tools, neurologic function assessments, and [ncf]{.smallcaps} tests were also used in many clinical trials to evaluate the well-being of patients. Some studies have shown that certain parameters of [qol]{.smallcaps} deteriorate after [wbrt]{.smallcaps} in patients with poorer prognosis, but other studies have shown that [qol]{.smallcaps} in patients with better prognosis improve after [wbrt]{.smallcaps}. Although a number of validated [qol]{.smallcaps} questionnaires specific to the concerns of metastatic brain cancer patients have been developed, no standard questionnaire has currently been established for this patient population, making comparisons of [qol]{.smallcaps} across trials difficult. Our findings emphasize the importance of including [qol]{.smallcaps} as an endpoint in future clinical trials so as to better understand the role of [qol]{.smallcaps}, especially for improving treatment in patients with brain metastases.
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###### 

Studies involving patients with a single brain metastasis

  Reference                                         Study arms                                                                                      Patients (n)                                        Survival                                        Tools                                                  [qol]{.smallcaps} instruments (n)                                                                   
  ------------------------------------------------- ----------------------------------------------------------------------------------------------- --------------------------------------------------- ------------------------------ ---------------- ------------------------------------------------------ ------------------------------------ -------------------------------------------------------------- ---
  Auchter *et al.*, 1996 [@b36-co15-5-226e25]       Radiosurgery + [wbrt]{.smallcaps} (range: 25--40 Gy)                                            122 [a](#tfn1-co15-5-226e25){ref-type="table-fn"}   14                             (53 at 1 year)   [kps]{.smallcaps}                                                                           Duration of functional independence Cause of death             1
  Epstein *et al.*, 1993 [@b35-co15-5-226e25]       32 Gy in 20 fractions [bid]{.smallcaps} + boost:                                                                                                                                                    [kps]{.smallcaps}                                      Neurologic function classification                                                                  2
                                                     48 Gy                                                                                          30                                                  4.9                                                                                                                                                                                                        
                                                     54.4 Gy                                                                                        53                                                  5.4                                                                                                                                                                                                        
                                                     64 Gy                                                                                          44                                                  7.2                                                                                                                                                                                                        
                                                     70.4 Gy                                                                                        26                                                  8.2                                                                                                                                                                                                        
  Jyothirmayi *et al.*, 2001 [@b37-co15-5-226e25]   Radiosurgery (at diagnosis)                                                                     45                                                  10                                              [kps]{.smallcaps}                                                                           Overall response rate                                          1
                                                    Radiosurgery + [wbrt]{.smallcaps}[b](#tfn2-co15-5-226e25){ref-type="table-fn"} (at diagnosis)   22                                                  8                                                                                                                                           Toxicity                                                       
                                                    Radiosurgery (at recurrence)                                                                    29                                                  7                                                                                                                                                                                                          
  Li *et al.*, 2000 [@b38-co15-5-226e25]            35--45 Gy/18--25 fractions                                                                      29                                                  5.7 (*p\<*0.0001)                               [kps]{.smallcaps}                                                                           Intracranial progression-free duration Overall response rate   1
                                                    Radiosurgery                                                                                    23                                                  9.3                                                                                                                                         Cause of death                                                 
                                                    Radiosurgery + 30--45 Gy/15--25 fractions                                                       18                                                  10.6                                                                                                                                                                                                       
  Mintz *et al.*, 1996 [@b29-co15-5-226e25]         30 Gy/10 fractions + surgery                                                                    41                                                  5.6 *p=* ( [ns]{.smallcaps})   19 (46)          Spitzer's QL index                                                                          Cause of death                                                 2
                                                    30 Gy/10 fractions                                                                              43                                                  6.3                            23 (53)          [kps]{.smallcaps}                                                                                                                                          
  Noordijk *et al.*, 1994 [@b23-co15-5-226e25]      40 Gy/20 fractions [bid]{.smallcaps} + surgery                                                  32                                                  10                             21 (66)          [ecog]{.smallcaps}                                     Neurologic function classification   Cause of death                                                 3
                                                    40 Gy/20 fractions [bid]{.smallcaps}                                                            31                                                  6                              16 (52)          [fis]{.smallcaps}                                                                                                                                          
  Patchell *et al.*, 1990 [@b34-co15-5-226e25]      36 Gy/12 fractions + surgery                                                                    25                                                  9.2 (*p\<*0.01)                17 (68)          [kps]{.smallcaps}                                                                           Duration of functional independence Cause of death             1
                                                    36 Gy/12 fractions                                                                              23                                                  3.5                            5 (22)                                                                                                                                                                      
  Patchell *et al.*, 1998 [@b19-co15-5-226e25]      Surgery + 54 Gy/28 fractions                                                                    49                                                  48 weeks (*p=*0.39)                             [kps]{.smallcaps}                                                                           Cause of death                                                 1
                                                    Surgery                                                                                         46                                                  43 weeks                                                                                                                                                                                                   
  Roos *et al.*, 2006 [@b39-co15-5-226e25]          36 Gy/18 fractions                                                                              10                                                  9.2 (*p=* NS)                                   [ecog]{.smallcaps}                                                                          [mmse]{.smallcaps}                                             3
                                                    Control group (1 in each arm, surgery; 17 patients had radiosurgery)                            9                                                   6.2                                             [eortc qlq]{.smallcaps}-C30 and [bcm]{.smallcaps} 20                                                                                                       

5 Patients declined [wbrt]{.smallcaps}, but were included in the study.

76% of the study population received 20 Gy/ 2 fr.

abstract only.

[qol]{.smallcaps} = quality of life; [wbrt]{.smallcaps} = whole-brain radiation therapy; [kps]{.smallcaps} = Karnofsky performance status; [bid]{.smallcaps} = twice daily; [ecog]{.smallcaps} = Eastern Cooperative Oncology Group; [ns]{.smallcaps} = nonsignificant; [fis]{.smallcaps} = Functionally Independent Survival; [eortc qlq]{.smallcaps}-30 = European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire; [eortc bcm]{.smallcaps} 20 = European Organization for Research and Treatment of Cancer Brain Cancer Module.

###### 

Studies of whole-brain altered-fractionation radiotherapy for brain metastases

  Reference                                                Study arms                                                                                                                                                                       Patients (n)           Survival                                                                 Tools     [qol]{.smallcaps}                                         
  -------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ------------------------------------------------------------------------ --------- -------------------- ------------------------------------ ---
  Bach *et al.,* 1996 [@b51-co15-5-226e25]                 50.4 Gy/28 fractions, 5 fractions/week                                                                                                                                           44                     160 days (74--2021 days) [a](#tfn5-co15-5-226e25){ref-type="table-fn"}             [ecog]{.smallcaps}                                        1
                                                           22 Gy/4 fractions                                                                                                                                                                57                     88 days                                                                                                                                      
                                                           [sclc]{.smallcaps} patients post-chemotherapy                                                                                                                                    *(p*\<0.00001)         (20--948 days),                                                                                                                              
  Borgelt *et al.,*                                        Study 1:                                                                                                                                                                                                                                                                                                                                             
  1980[@b10-co15-5-226e25]                                  30 Gy/10 fractions                                                                                                                                                              233                    4.2 months                                                                         [gps]{.smallcaps}    Neurologic function classification   2
                                                            30 Gy/15 fractions                                                                                                                                                              217                    (3.7--4.6 months)                                                                                                                            
                                                            40 Gy/15 fractions                                                                                                                                                              233                    *(p*\>0.05)                                                                                                                                  
                                                            40 Gy/20 fractions                                                                                                                                                              227                                                                                                                                                                 
                                                           Study 2:                                                                                                                                                                                                                                                                                                                                             
                                                            20 Gy/5 fractions                                                                                                                                                               447                    3.5 months                                                                                                                                   
                                                            30 Gy/10 fractions                                                                                                                                                              228                    (3.2--3.5 months)                                                                                                                            
                                                            40 Gy/15 fractions                                                                                                                                                              227                    *(p*\>0.05)                                                                                                                                  
  Borgelt *et al.,* 1981 [@b44-co15-5-226e25]              Study 1:                                                                                                                                                                                                                                                                                   [gps]{.smallcaps}    Neurologic function classification   2
                                                            10 Gy/1 fractions                                                                                                                                                               26                     3.5 months                                                                                                                                   
                                                            30--40 Gy/10--20 fractions                                                                                                                                                      112                    4.8 months *(p*\>0.05)                                                                                                                       
                                                           Study 2:                                                                                                                                                                                                                                                                                                                                             
                                                            12 Gy/2 fractions                                                                                                                                                               33                     3.0 months                                                                                                                                   
                                                            20 Gy/5 fractions                                                                                                                                                               31                     2.8 months *(p*\>0.05)                                                                                                                       
  Chatani *et al.,* 1994 [@b45-co15-5-226e25] (abstract)   Normal lactate dehydrogenase ([ldh]{.smallcaps}):                                                                                                                                                                                                                                                                                                    0
                                                            30 Gy/10 fractions                                                                                                                                                              46                     5.4 months                                                               19 (41)                                                             
                                                            50 Gy/20 fractions                                                                                                                                                              46                     4.8 months *(p*=0.841)                                                   22 (48)                                                             
                                                           High [ldh]{.smallcaps}                                                                                                                                                                                                                                                                                                                               
                                                            30 Gy/10 fractions                                                                                                                                                              35                     3.4 months                                                               7 (20)                                                              
                                                            50 Gy/20 fractions                                                                                                                                                              35                     2.4 months *(p*=0.943)                                                   7 (20)                                                              
  Gelber *et al.,* 1981 [@b46-co15-5-226e25]               20 Gy/5 fractions                                                                                                                                                                Breast patients: 160   33 weeks                                                                           [gps]{.smallcaps}    Neurologic function classification   2
                                                           30 Gy/10 fractions                                                                                                                                                               Lung patients: 556     20 weeks                                                                                                                                     
                                                           30 Gy/15 fractions                                                                                                                                                               Other patients: 213    20 weeks                                                                                                                                     
                                                           40 Gy/15 fractions                                                                                                                                                                                                                                                                                                                                   
                                                           40 Gy/20 fractions                                                                                                                                                                                                                                                                                                                                   
  Haie--Meder *et al.,* 1993 [@b28-co15-5-226e25]          1 course:                                                                                                                                                                                                                                                                                                                                            
                                                            18 Gy/3 fractions/3 days                                                                                                                                                        110                    4.2 months                                                               53 (48)   [kps]{.smallcaps}                                         1
                                                           2 courses:                                                                                                                                                                                              *(p*\>0.05)                                                                                                                                  
                                                            18 Gy/3 fractions/3 days followed 1 month later by another 18 Gy/3 fractions/3 days, or 18 Gy/3 fractions/3 days followed 1 month later by another 25 Gy/10 fractions/14 days   106                    5.3 months                                                               41 (38)                                                             
  Harwood *et al.,* 1977 [@b22-co15-5-226e25]              10 Gy/1 fractions                                                                                                                                                                51                     4.4 months *(p*=0.082)                                                   14 (27)   Functional status    Neurologic function classification   2
                                                           30 Gy/10 fractions                                                                                                                                                               50                     4.0 months                                                               20 (40)                                                             
  Kurtz *et al.,* 1981 [@b50-co15-5-226e25]                30 Gy/10 fractions                                                                                                                                                               130                    18 weeks *(p* = [ns]{.smallcaps})                                                  Performance status   Neurologic function classification   2
                                                           50 Gy/20 fractions                                                                                                                                                               125                    17 weeks                                                                                                                                     
  Murray *et al.,* 1997 [@b6-co15-5-226e25]                54.4 Gy/34 fractions [bid]{.smallcaps} (over 17 days)                                                                                                                            216                    4.5 months *(p*=0.52)                                                    84 (39)   [kps]{.smallcaps}    Neurologic function classification   2
                                                           30 Gy/10 fractions (over 10 days)                                                                                                                                                213                    4.5 months                                                               88 (41)                                                             
  Nieder *et al.,* 1997 [@b47-co15-5-226e25]               30 Gy/12 fractions [bid]{.smallcaps} + surgery                                                                                                                                   11                     3.3 months                                                                         [kps]{.smallcaps}                                         1
                                                           30 Gy/12 fractions [bid]{.smallcaps}                                                                                                                                             36                     2.0 months                                                                                                                                   
                                                           50.4 Gy/28 fractions [bid]{.smallcaps}                                                                                                                                           15                     2.0 months                                                                                                                                   
                                                           30 Gy/10 fractions (historical group)                                                                                                                                            246                    2.5 months                                                                                                                                   
                                                           30 Gy/10 fractions + surgery (historical group)                                                                                                                                  37                     7.3 months                                                                                                                                   
  Portaluri *et al.,* 2004 [@b48-co15-5-226e25]            50 Gy/25 fractions                                                                                                                                                               26                     4 months (mean survival)                                                 6 (21)                         Neurologic function classification   1
                                                           30 Gy/10 fractions                                                                                                                                                               48                     5 months                                                                 18 (36)                                                             
                                                           20 Gy/5 fractions                                                                                                                                                                42                     5 months                                                                 9 (21)                                                              
                                                           9 Unusual fractionation treatments [b](#tfn6-co15-5-226e25){ref-type="table-fn"}                                                                                                                                                                                                                                                                     
  Priestman *et al.,* 1996 [@b49-co15-5-226e25]            30 Gy/10 fractions                                                                                                                                                               263                    2.8 months *(p*=0.04)                                                    46 (17)   ECOG                 Neurologic function classification   2
                                                           12 Gy/2 fractions                                                                                                                                                                270                    2.5 months                                                               66 (25)                                                             

Measured from the diagnosis of brain metastases.

Exact dose and fractionation schedule not described.

[qol]{.smallcaps} = quality of life; [sclc]{.smallcaps} = small-cell lung cancer; [ecog]{.smallcaps} = Eastern Cooperative Oncology Group assessment; [gps]{.smallcaps} = General Performance Status; [kps]{.smallcaps} = Karnofsky performance status; [ns]{.smallcaps} = nonsignificant; [bid]{.smallcaps} = twice daily.

###### 

Multiple brain metastases: studies of whole-brain radiotherapy ([wbrt]{.smallcaps}) with radiosensitizers compared with [wbrt]{.smallcaps} alone

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                      Study arms                                                                    Patients (n)                                        Median survival                      Overall response rate ([cr]{.smallcaps}+[pr]{.smallcaps} %)          [qol]{.smallcaps} assessment   Tools Neurologic function or symptom control                                         Other assessment          [qol]{.smallcaps} instruments (n)
  ---------------------------------------------- ----------------------------------------------------------------------------- --------------------------------------------------- ------------------------------------ -------------------------------------------------------------------- ------------------------------ ------------------------------------------------------------------------------------ ------------------------- -----------------------------------
  DeAngelis *et al.,* 1989 [@b9-co15-5-226e25]   30 Gy/10 fractions + lonidamine\                                              19                                                  4.0 months *(p*= [ns]{.smallcaps})   37% (11.5 patients)                                                  [kps]{.smallcaps}                                                                                                   Cause of death Toxicity   1
                                                 30 Gy/10 fractions                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                               20                                                  5.4 months                           55% (15 patients)                                                                                                                                                                                                  

  Eyre *et al.,* 1984 [@b24-co15-5-226e25]       30 Gy/10 fractions + metronidazole\                                           57                                                  2.8 months *(p*= [ns]{.smallcaps})   27% (15 patients)                                                                                   Neurologic function classification                                                   Cause of death Toxicity   1
                                                 30 Gy/10 fractions                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                               54                                                  3.2 months                           24% (13 patients)                                                                                                                                                                                                  

  Johnson *et al.,* 1998 [@b52-co15-5-226e25]    [wbrt]{.smallcaps} + pentoxifylline                                           14                                                  33 days                              14% (2 patients)                                                     [ecog]{.smallcaps}             Neurologic function classification                                                                             2

  Kocher *et al.,* 2005 [@b53-co15-5-226e25]     36 Gy/12 fractions + topotecan                                                47                                                  5.1 months                           58% (15 patients)                                                    [kps]{.smallcaps}                                                                                                   Cause of death Toxicity   1

  Phillips *et al.,* 1995 [@b21-co15-5-226e25]   37.5 Gy/15 fractions + bromodeoxyuridine\                                     34                                                  4.3 months *(p*= [ns]{.smallcaps})   63% of 22 patients evaluable for response (14 patients)              [kps]{.smallcaps}              Neurologic function classification                                                   Toxicity                  2
                                                 37.5 Gy/15 fractions                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                               36                                                  6.12 months                          50% of 24 patients evaluable for response (12 patients)                                                                                                                                                            

  Rhomberg *et al.,* 2005 [@b25-co15-5-226e25]   30 Gy/30 fractions + boost series of 2 Gy/dose, median of 43 Gy + razoxane\   8                                                   5 months *(p*= [ns]{.smallcaps})     62% (5 patients)                                                     [kps]{.smallcaps}              Score Index for Stereotactic Radiosurgery ([sir]{.smallcaps}) for Brain Metastasis   Toxicity                  1
                                                 30 Gy/30 fractions + boost series of 2 Gy/dose, median dose of 35 Gy                                                                                                                                                                                                                                                                                                                      

                                                                                                                               11                                                  2.2 months                           27% (3 patients)                                                                                                                                                                                                   

  Stea *et al.,* 2006 [@b54-co15-5-226e25]       30 Gy/10 fractions + efaproxiral\                                             265 [a](#tfn8-co15-5-226e25){ref-type="table-fn"}                                        74% (27.9 patients) [c](#tfn10-co15-5-226e25){ref-type="table-fn"}                                                                                                                                                 
                                                 30 Gy/10 fractions                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                               250 [b](#tfn9-co15-5-226e25){ref-type="table-fn"}                                        50% (20 patients) [b](#tfn9-co15-5-226e25){ref-type="table-fn"}      [kps]{.smallcaps}                                                                                                                             1
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

18 Patients had radiosurgery and 3 patients had surgical resection after randomization.

13 Patients had radiosurgery and 9 patients had surgical resection after randomization.

Response rate determined 3 months after treatment.

[cr]{.smallcaps} = complete response; [pr]{.smallcaps} = partial response; [qol]{.smallcaps} = quality of life; [ns]{.smallcaps} = nonsignificant; [kps]{.smallcaps} = Karnofsky performance status; [ecog]{.smallcaps} = Eastern Cooperative Oncology Group assessment.

###### 

Multiple brain metastases: studies assessing the efficacy of whole-brain radiotherapy ([wbrt]{.smallcaps}) and chemotherapy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                      Study criteria                                Study arms                                               Patients (n)                       Median survival                     Overall response rate ([cr]{.smallcaps}+[pr]{.smallcaps})   [qol]{.smallcaps} assessment                  Tools Neurologic function or symptom control   Other assessment                     [qol]{.smallcaps} instruments (n)
  ---------------------------------------------- --------------------------------------------- -------------------------------------------------------- ---------------------------------- ----------------------------------- ----------------------------------------------------------- --------------------------------------------- ---------------------------------------------- ------------------------------------ -----------------------------------
  Addeo *et al.,* 2007[@b55-co15-5-226e25]       Metastatic cancer to the brain                30 Gy/10 fractions + temozolomide                        59                                 13 months                           44%                                                         [kps]{.smallcaps}\                                                                           Toxicity                             2
                                                                                                                                                                                                                                                                                           [fact]{.smallcaps}-[g]{.smallcaps}\                                                                                               
                                                                                                                                                                                                                                                                                           [fact]{.smallcaps}-[br]{.smallcaps}                                                                                               

  Antonadou *et al.,* 2002[@b56-co15-5-226e25]   Metastatic cancer to the brain                30 Gy/10 fractions + temozolomide                        Total of 134 patients randomized   8.3 months                          53.4%                                                       [kps]{.smallcaps}                                                                                                                 1

                                                                                               30 Gy/10 fractions                                                                          6.3 months (*p*=0.179)              33.3% (*p*=0.039)                                                                                                                                                                             

  Guerrieri *et al.,* 2003[@b57-co15-5-226e25]   Metastatic [nsclc]{.smallcaps} to the brain   20 Gy/5 fractions + carboplatin                          21                                 3.7 months                          29%                                                         [ecog]{.smallcaps}                            Neurologic function classification             Toxicity                             2

                                                                                               20 Gy/5 fractions                                        21                                 4.4 months (*p*=0.64)               10% (*p*=0.24)                                                                                                                                                                                

  Hidalgo *et al.,* 1987[@b58-co15-5-226e25]     Metastatic cancer to the brain                50 Gy/25 fractions + *cis-*platinum                      13                                 [n]{.smallcaps}/[a]{.smallcaps}     92.3% (12 patients)                                         [kps]{.smallcaps}                                                                            Toxicity                             1

  Postmus *et al.,* 2000[@b8-co15-5-226e25]      Metastatic [sclc]{.smallcaps} to the brain    30 Gy/10 fractions + teniposide                          60                                 3.5 months                          57%                                                         [ecog]{.smallcaps}                            Neurologic function classification             Toxicity Duration till progression   2

                                                                                               Teniposide                                               60                                 3.2 months (*p*=0.087)              22% (*p*\<0.001)                                                                                                                                                                              

  Robinet *et al.,* 2001[@b7-co15-5-226e25]      Metastatic [nsclc]{.smallcaps} to the brain   Delayed 30 Gy/10 fractions + cisplatin and vinorelbine   76                                 6.0 months                          33%                                                         [ecog]{.smallcaps}                            Order classification                           Toxicity                             2

                                                                                               Early 30 Gy/10 fractions + cisplatin and vinorelbine     73                                 5.3 months (*p*=0.83)               27% (*p*=0.12)\                                                                                                                                                                               
                                                                                                                                                                                                                               Intracranial response rate                                                                                                                                                                    

  Ushio *et al.,* 1991[@b60-co15-5-226e25]       Metastatic lung cancer to the brain           40 Gy total (1.5--2 Gy per dose)                         31                                 27 weeks                            36%                                                                                                                                                                                           0

                                                                                               [wbrt]{.smallcaps} + chloroethylnitrosoureas             36                                 29 weeks                            69%                                                                                                                                                                                           

                                                                                               [wbrt]{.smallcaps} + chloroethylnitrosoureas + tegafur   33                                 24 weeks (*p*=[ns]{.smallcaps})     74% (*p*\<0.05)\                                                                                                                                                                              
                                                                                                                                                                                                                               Brain metastases regression                                                                                                                                                                   

  Verger *et al.,* 2004[@b59-co15-5-226e25]      Metastatic cancer to the brain                30 Gy/10 fractions + temozolomide                        41                                 4.5 months                          32%                                                         [kps]{.smallcaps}                                                                            Toxicity                             2

                                                                                               30 Gy/10 fractions                                       41                                 3.1 months (*p*=[ns]{.smallcaps})   32% (*p*=[ns]{.smallcaps} at 30 days)                       Barthel index of activities of daily living                                                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[cr]{.smallcaps} = complete response; [pr]{.smallcaps} = partial response; [qol]{.smallcaps} = quality of life; [fact]{.smallcaps}-[g]{.smallcaps} = Functional Assessment of Cancer Therapy---General scale; [fact]{.smallcaps}-[br]{.smallcaps} = Functional Assessment of Cancer Therapy---Brain subscale; [kps]{.smallcaps} = Karnofsky performance status; [nsclc]{.smallcaps} = non-small-cell lung cancer; [ecog]{.smallcaps} = Eastern Cooperative Oncology Group assessment; [sclc]{.smallcaps} = small-cell lung cancer; [ns]{.smallcaps} = nonsignificant.

###### 

Multiple brain metastases: studies assessing the efficacy of whole-brain radiotherapy ([wbrt]{.smallcaps}) with or without radiosurgery

  Reference                                        Study criteria          Study arms                                             Patients (n)   Median survival                        1-Year local control   [qol]{.smallcaps} assessment   Tools Neurologic function or symptom control   Other assessment   [qol]{.smallcaps} instruments (n)
  ------------------------------------------------ ----------------------- ------------------------------------------------------ -------------- -------------------------------------- ---------------------- ------------------------------ ---------------------------------------------- ------------------ -----------------------------------
                                                                           37.5 Gy/15 fractions                                   167            5.7 months                             71%                                                                                                                     
  Jawahar *et al.,* 2002 [@b66-co15-5-226e25]      Brain metastases        30 Gy/10 fractions                                     86             5 months (*p*=0.0016)                                         [kps]{.smallcaps}                                                             Cause of death     1
                                                                           Gamma knife radiosurgery                               48             12 months                                                                                                                                                      
  Kondziolka *et al.,* 1999 [@b20-co15-5-226e25]   2--4 Brain metastases   30 Gy/12 fractions + Gamma Knife radiosurgery          13             11.5 months (*p*=0.22)                 92% (*p*=0.01)                                                                                                          0
                                                                           30 Gy/12 fractions                                     14             7.5 months (*p*=[ns]{.smallcaps})      0%                                                                                                                      
  Pirzkall *et al.,* 1998 [@b67-co15-5-226e25]     1--3 Brain metastases   30--50 Gy total, median dose of 15 Gy + radiosurgery   78             5.5 months (entire study population)   92% (*p*=0.13)         [kps]{.smallcaps}                                                             Cause of death     1
                                                                           Radiosurgery                                           158                                                   89%                                                                                                                     
  Sneed *et al.,* 1999 [@b69-co15-5-226e25]        Brain metastases        Radiosurgery + [wbrt]{.smallcaps}                      43             11.1 months (*p*=0.80)                 69%                    [kps]{.smallcaps}                                                             Cause of death     1
                                                                           Radiosurgery                                           62             11.3 months                            28%                                                                                                                     

[qol]{.smallcaps} = quality of life; [kps]{.smallcaps} = Karnofsky performance status; [ns]{.smallcaps} = nonsignificant.

###### 

Multiple brain metastases: studies assessing the efficacy of re-irradiation ([ri]{.smallcaps})

  Reference                                          Study arms                                                                                   Population sample                  Overall median survival following [ri]{.smallcaps}   [qol]{.smallcaps} Assessment         Tools Neurologic function or symptom control   Other assessment        [qol]{.smallcaps} Instruments (n)
  -------------------------------------------------- -------------------------------------------------------------------------------------------- ---------------------------------- ---------------------------------------------------- ------------------------------------ ---------------------------------------------- ----------------------- -----------------------------------
  Abdel--Wahab *et al.,* 1997 [@b65-co15-5-226e25]   Initial course:                                                                              15                                 3.2 months                                           [kps]{.smallcaps}                                                                   Response to treatment   1
                                                      range 30--55 Gy, 1.5 Gy/fractions [bid]{.smallcaps}                                                                                                                                                                                                                                             
                                                     Whole-brain RI:                                                                                                                                                                                                                                                                                  
                                                      median 30 Gy                                                                                                                                                                                                                                                                                    
  Hazuka *et al.,* 1988 [@b61-co15-5-226e25]         Initial course:                                                                              37 whole-brain [ri]{.smallcaps}    8 weeks                                                                                                                                  Response to treatment   0
                                                      median 30 Gy                                                                                7 partial-brain [ri]{.smallcaps}                                                                                                                                                                    
                                                     Whole- or partial-brain [ri]{.smallcaps}:                                                                                                                                                                                                                                                        
                                                      median 25 Gy, 3.0 Gy/fractions                                                                                                                                                                                                                                                                  
  Kurup *et al.,* 1980 [@b62-co15-5-226e25]          Initial course:                                                                              56                                 3.5 months                                                                                                                               Response to treatment   0
                                                      18 Gy/3 fractions,                                                                                                                                                                                                                                                                              
                                                      20 Gy/5 fractions,                                                                                                                                                                                                                                                                              
                                                      30 Gy/10 fractions                                                                                                                                                                                                                                                                              
                                                     Whole-brain [ri]{.smallcaps}:                                                                                                                                                                                                                                                                    
                                                      Most patients received a single 5-Gy dose or 46 Gy/20 fractions (5 Gy/week)                                                                                                                                                                                                                     
  Rosenman *et al.,* 1982 [@b63-co15-5-226e25]       Initial course:                                                                                                                 Difference in survival:                                                                                                                                          
                                                      30 Gy/10 fractions                                                                                                                                                                  [kps]{.smallcaps}                                                                   Response to treatment   1
                                                      -- Elective whole-brain [ri]{.smallcaps}                                                    24                                 *p*=[ns]{.smallcaps}                                                                                                                                             
                                                      -- Therapeutic whole-brain [ri]{.smallcaps}[a](#tfn14-co15-5-226e25){ref-type="table-fn"}   28                                                                                                                                                                                                  
  Shehata *et al.,* 1974 [@b64-co15-5-226e25]        60% Whole-brain [ri]{.smallcaps} (single 10-Gy dose)                                         50                                 150 days                                             Neurologic function classification                                                  Response to treatment   1

Defined by authors, because patients were re-irradiated when brain metastases occurred.

[qol]{.smallcaps} = quality of life; [bid]{.smallcaps} = twice daily; [kps]{.smallcaps} = Karnofsky performance status; [ns]{.smallcaps} = nonsignificant.

###### 

Multiple brain metastases: studies focused on quality of life ([qol]{.smallcaps}), neurologic function, and neurocognitive function ([ncf]{.smallcaps})

  Reference                                        Study arms                                                                                                       Patients (n)   Median survival                                              [qol]{.smallcaps} assessment                                                                                         Tools Neurologic function or symptom control                                                                                              Other assessment                                                                 [qol]{.smallcaps} instruments (n)
  ------------------------------------------------ ---------------------------------------------------------------------------------------------------------------- -------------- ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------- -----------------------------------
  Bezjak *et al.,* 2002 [@b71-co15-5-226e25]       20 Gy/5 fractions                                                                                                75             86 days                                                      [ecog]{.smallcaps}                                                                                                   Neurologic symptom checklist modelled after the [fact-br]{.smallcaps} and [eortc bcm]{.smallcaps} 20 Neurologic function classification   Analgesic measurement                                                            5
                                                                                                                                                                                                                                                [fact-g]{.smallcaps}                                                                                                                                                                                                                                           [mmse]{.smallcaps}                                                               
                                                                                                                                                                                                                                                [fact-br]{.smallcaps}                                                                                                                                                                                                                                                                                                                           
  Chow *et al.,* 2005 [@b17-co15-5-226e25]         20 Gy/5 fractions (*n*=138)                                                                                      170            8 weeks                                                      [kps]{.smallcaps}                                                                                                                                                                                                                                                                                                                               2
                                                   30 Gy/10 fractions (*n*=7)                                                                                                                                                                   [esas]{.smallcaps}                                                                                                                                                                                                                                                                                                                              
                                                   Other dose fractionations (*n*=25)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Gerrard *et al.,* 2003 [@b72-co15-5-226e25]      First study:                                                                                                                                                                                 [kps, eortc qlq]{.smallcaps}-30, and [bcm]{.smallcaps} 20                                                                                                                                                                                                                                                                                       4
                                                    12 Gy/2 fractions                                                                                               18             6 weeks                                                                                                                                                                                                                                                                                                                                                                                                      
                                                   Second study:                                                                                                                                                                                [kps]{.smallcaps}, Barthel index of activity of daily living, [eortc qlq]{.smallcaps}-30, and [bcm]{.smallcaps} 20   Neurologic function classification                                                                                                        Time to progression                                                              
                                                    20 Gy/5 fractions                                                                                               6              8 weeks                                                                                                                                                                                                                                                                                                                     Analgesic measurement                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Side effects of treatment                                                        
                                                   Third study:                                                                                                                                                                                 [kps]{.smallcaps}, Barthel index of activity of daily living, questions 29 and 30 of [qlc]{.smallcaps}-C30                                                                                                                                                     Analgesic measurement                                                            
                                                    12 Gy/2 fractions or 20 Gy/5 fractions                                                                          14             10 weeks                                                                                                                                                                                                                                                                                                                    Side effects of steroid and treatment                                            
  Kondziolka *et al.,* 2005 [@b68-co15-5-226e25]   30 Gy/12 fractions or 10 fractions and Gamma Knife radiosurgery [a](#tfn16-co15-5-226e25){ref-type="table-fn"}   72                                                                          [kps]{.smallcaps}                                                                                                                                                                                                                                                                                                                               2
                                                   Gamma Knife radiosurgery [a](#tfn16-co15-5-226e25){ref-type="table-fn"}                                          32                                                                          Study-designed questionnaire                                                                                                                                                                                                                                                                                                                    
  Li *et al.,* 2007 [@b76-co15-5-226e25]           Motexafin gadolinium and 30Gy/10 fractions                                                                       208            Good responders:                                             [kps]{.smallcaps}                                                                                                                                                                                                                                              [ncf]{.smallcaps} test battery [b](#tfn17-co15-5-226e25){ref-type="table-fn"}:   5
                                                                                                                                                                                   300±26 days [c](#tfn18-co15-5-226e25){ref-type="table-fn"}                                                                                                                                                                                                                                                                  [hvlt]{.smallcaps}, Trailmaking A and B, Grooved Pegboard, [cowa]{.smallcaps}    
                                                                                                                                                                                   Poor responders:                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                   240±19 days                                                                                                                                                                                                                                                                                                                                                                                                  
  Lock *et al.,* 2004 [@b73-co15-5-226e25]         [wbrt]{.smallcaps}---                                                                                            275            5.3 months                                                   [ecog]{.smallcaps}                                                                                                                                                                                                                                                                                                                              1
                                                    most frequent dose fractionation:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                    20 Gy/5 fractions (6% of patients received 30 Gy/10 fractions; 6% received other schedules)                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Murray *et al.,* 1999 [@b27-co15-5-226e25]       30 Gy/10 fractions                                                                                               182            4.2 months                                                   [kps]{.smallcaps}                                                                                                                                                                                                                                              [mmse]{.smallcaps}                                                               2
  Regine *et al.,* 2004 [@b77-co15-5-226e25]       37.5 Gy/15 fractions (2.5 Gy/fraction)                                                                           55                                                                          [ecog]{.smallcaps}                                                                                                   Neurologic function classification                                                                                                        [ncf]{.smallcaps} test battery [b](#tfn17-co15-5-226e25){ref-type="table-fn"}:   8
                                                                                                                                                                                                                                                [poms-sf]{.smallcaps}                                                                                                                                                                                                                                          [mmse, hvlt, cowa]{.smallcaps}, Ruff 2 and 7 and Trailmaking A and B             
  Scott *et al.,* 2007 [@b70-co15-5-226e25]        30 Gy/10 fractions + efaproxiral                                                                                 57             9.0 months                                                   [kps]{.smallcaps}                                                                                                    Neurologic function classification                                                                                                        [mmse]{.smallcaps}                                                               4
                                                   30 Gy/10 fractions                                                                                               49             4.5 months *(p*=0.004)                                       Spitzer Q-L index                                                                                                                                                                                                                                                                                                                               
  Sehlen *et al.,* 2003 [@b74-co15-5-226e25]       [cns]{.smallcaps} primary and radiotherapy                                                                       24             26.4 months [d](#tfn19-co15-5-226e25){ref-type="table-fn"}   [kps, fact-g]{.smallcaps}                                                                                                                                                                                                                                      [mmsi]{.smallcaps} (modified abbreviated version)                                4
                                                   Brain metastases and radiotherapy                                                                                33             28.3 months *(p*=[ns]{.smallcaps})                           Current Situation in Personal Life questionnaire                                                                                                                                                                                                                                                                                                
  Yaneva *et al.,* 2006 [@b75-co15-5-226e25]       30 Gy/10 fractions or 15 fractions                                                                               65             6.6 months [e](#tfn20-co15-5-226e25){ref-type="table-fn"}    [kps]{.smallcaps}                                                                                                                                                                                                                                                                                                                               2
                                                                                                                                                                                   9.8 months [f](#tfn21-co15-5-226e25){ref-type="table-fn"}    [eortc qlq]{.smallcaps}-C30                                                                                                                                                                                                                                                                                                                     

2--4 Brain metastases.

Authors believed [ncf]{.smallcaps} and [qol]{.smallcaps} correlated in this population.

Good responders showed tumour shrinkage above the population median; poor responders showed tumour shrinkage below the population median.

Survival length is unexpectedly long (attributable to the patient sample, which contains patients with anaplastic astrocytomas (34.4%) and brain tumours of a different histologic origin (12.5%).

Lung cancer patients.

Breast cancer patients.

[qol]{.smallcaps} = quality of life; [ecog]{.smallcaps} = Eastern Cooperative Oncology Group Assessment; [fact]{.smallcaps}-[g]{.smallcaps} = Functional Assessment of Cancer Therapy---General scale; [fact]{.smallcaps}-[br]{.smallcaps} = Functional Assessment of Cancer Therapy---Brain subscale; [eortc bcm]{.smallcaps} 20 = European Organization for Research and Treatment of Cancer Brain Cancer Module; [mmse]{.smallcaps} = Mini Mental Status Examination; [kps]{.smallcaps} = Karnofsky performance status; [esas]{.smallcaps} = Edmonton Symptom Assessment Scale; [eortc qlq]{.smallcaps}-30 = European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire; [hvlt]{.smallcaps} = Hopkins Verbal Learning Test; [cowa]{.smallcaps} = Controlled Oral Word Association; [wbrt]{.smallcaps} = whole-brain radiotherapy; [poms]{.smallcaps}-[sf]{.smallcaps} = Profile of Mood States--Short Form; [mmsi]{.smallcaps} = Mini Mental State Inventory; [ns]{.smallcaps} = nonsignificant.

###### 

Studies focused on managing brain metastases through corticosteroids

  Reference                                     Study arms                                                  Patients (n)   Median survival               Overall response rate ([cr]{.smallcaps}+[pr]{.smallcaps})   [qol]{.smallcaps} assessment   Tools Neurologic function or symptom control   Other assessment          [qol]{.smallcaps} instruments (n)
  --------------------------------------------- ----------------------------------------------------------- -------------- ----------------------------- ----------------------------------------------------------- ------------------------------ ---------------------------------------------- ------------------------- -----------------------------------
  Horton *et al.,* 1971 [@b40-co15-5-226e25]    Oral prednisone and [wbrt]{.smallcaps}                      48 (total)     14 weeks                                                                                  Performance status                                                            Toxicity                  1
                                                Oral prednisone                                                            10 weeks                                                                                                                                                                Incidence of remissions   
  Wolfson *et al.,* 1994 [@b41-co15-5-226e25]   All patients:                                                              4 months (total population)   3 [cr]{.smallcaps}                                          [gps]{.smallcaps}              Neurologic function classification                                       2
                                                 dexamethasone every 6 hours for 48 hours                                                                1 [pr]{.smallcaps}                                                                                                                                                  
                                                                                                                                                         8 no response                                                                                                                                                       
                                                Arm 1:                                                      7                                                                                                                                                                                                                
                                                 4 mg every 6 hours dexamethasone with 30 Gy/10 fractions                                                                                                                                                                                                                    
                                                Arm 2:                                                      5                                                                                                                                                                                                                
                                                 30 Gy/10 fractions                                                                                                                                                                                                                                                          

[cr]{.smallcaps} = complete response; [pr]{.smallcaps} = partial response; [qol]{.smallcaps} = quality of life; [wbrt]{.smallcaps} = whole-brain radiotherapy; [gps]{.smallcaps} = General Performance Status.

###### 

Multiple brain metastases: studies assessing the efficacy of multiple treatments

  References                                  Study arms                                                            Patients (n)   Median survival                                               [qol]{.smallcaps} assessment   Tools Neurologic function or symptom control   [qol]{.smallcaps} instruments (n)
  ------------------------------------------- --------------------------------------------------------------------- -------------- ------------------------------------------------------------- ------------------------------ ---------------------------------------------- -----------------------------------
  Chang *et al.,* 1992 [@b42-co15-5-226e25]   [nsclc]{.smallcaps} patients                                                                                                                       [gps]{.smallcaps}              Neurologic function classification             2
                                               Surgery (4 patients received 30 Gy/15 fractions)                     9              9 months                                                                                                                                    
                                               Chemotherapy (4 patients received 30 Gy/15 fractions)                10             10 months                                                                                                                                   
                                               30 Gy/15 fractions                                                   12             7 months [a](#tfn24-co15-5-226e25){ref-type="table-fn"}                                                                                     
                                               Supportive care (2 patients received a ventriculoperitoneal shunt)   19             2 months                                                                                                                                    
  Routh *et al.,* 1994 [@b43-co15-5-226e25]   [wbrt]{.smallcaps}                                                    223            2.5 months                                                                                                                                  0
                                              Cisplatin, etoposide + [wbrt]{.smallcaps}                             5              (entire study population, from start of [wbrt]{.smallcaps})                                                                                 
                                              [wbrt]{.smallcaps} + [wbri]{.smallcaps}                               16                                                                                                                                                         
                                              [wbrt]{.smallcaps} + surgery                                          32                                                                                                                                                         

Difference between the three treatment modalities was nonsignificant.

[qol]{.smallcaps} = quality of life; [nsclc]{.smallcaps} = non-small-cell lung cancer; [gps]{.smallcaps} = General Performance Status; [wbrt]{.smallcaps} = whole-brain radiotherapy; [wbri]{.smallcaps} = whole-brain re-irradiation.

###### 

Frequency of instruments used in clinical trials measuring quality of life ([qol]{.smallcaps}) in patients with brain metastases

  Instrument                                                                                                                  Frequency
  --------------------------------------------------------------------------------------------------------------------------- -----------
  Karnofsky performance status                                                                                                33
  Neurologic function classification                                                                                          21
  [ecog]{.smallcaps} (World Health Organization) performance scores                                                           11
  General Performance Status                                                                                                  5
  Mini Mental Status Examination                                                                                              5
  Study-designed performance instrument [@b22-co15-5-226e25],[@b23-co15-5-226e25],[@b40-co15-5-226e25],[@b50-co15-5-226e25]   4
  Barthel index of activity of daily living                                                                                   2
  Controlled Oral Word Association test                                                                                       2
  Hopkins Verbal Learning Test                                                                                                2
  Spitzer quality of life index                                                                                               2
  Study-designed [qol]{.smallcaps} assessment [@b68-co15-5-226e25],[@b74-co15-5-226e25]                                       2
  Trailmaking A and B                                                                                                         2
  Edmonton Symptom Assessment Scale                                                                                           1
  [eortc]{.smallcaps} Core Quality of Life Questionnaire                                                                      1
   with Brain Cancer Module                                                                                                   2
  Functional Assessment of Cancer Therapy--General scale                                                                      1
   With Brain subscale                                                                                                        2
  Grooved Pegboard                                                                                                            1
  Mini Mental State Inventory (modified abbreviated version)                                                                  1
  Order classification                                                                                                        1
  Profile of Mood States--Short Form                                                                                          1
  Ruff 2 and 7                                                                                                                1
  Study-designed neurologic instrument [@b71-co15-5-226e25]                                                                   1

[ecog]{.smallcaps} = Eastern Cooperative Oncology Group; [eortc]{.smallcaps} = European Organization for Research and Treatment of Cancer.

###### 

Frequency of instruments used in assessing quality of life ([qol]{.smallcaps}) in clinical trials

  Instrument                                                                              Frequency
  --------------------------------------------------------------------------------------- -----------
  Spitzer quality of life index                                                           2
  Study-designed [qol]{.smallcaps} assessment [@b68-co15-5-226e25],[@b74-co15-5-226e25]   2
  Edmonton Symptom Assessment Scale                                                       1
  [eortc]{.smallcaps} Core Quality of Life Questionnaire                                  1
   with Brain Cancer Module                                                               2
  Functional Assessment of Cancer Therapy--General scale                                  1
   with Brain subscale                                                                    2
  Profile of Mood States--Short Form                                                      1

[eortc]{.smallcaps} = European Organization for Research and Treatment of Cancer.

###### 

Frequency of performance score instruments used in clinical trials

  Instrument                                                                                                                  Frequency
  --------------------------------------------------------------------------------------------------------------------------- -----------
  Karnofsky performance status                                                                                                33
  [ecog]{.smallcaps} (World Health Organization) performance score                                                            11
  General Performance Status                                                                                                  5
  Study-designed performance instrument [@b22-co15-5-226e25],[@b23-co15-5-226e25],[@b40-co15-5-226e25],[@b50-co15-5-226e25]   4
  Barthel index of activity of daily living                                                                                   2

[ecog]{.smallcaps} = Eastern Cooperative Oncology Group.

###### 

Frequency of neurologic function instruments used in clinical trials

  Instrument                                                  Frequency
  ----------------------------------------------------------- -----------
  Neurologic function classification                          21
  Order classification                                        1
  Study-designed neurologic instrument [@b71-co15-5-226e25]   1

###### 

Frequency of neurocognitive function instruments used in clinical trials

  Instrument                                                   Frequency
  ------------------------------------------------------------ -----------
  Mini Mental Status Examination                               5
  Controlled Oral Word Association test                        2
  Hopkins Verbal Learning Test                                 2
  Trailmaking A and B                                          2
  Grooved Pegboard                                             1
  Mini Mental State Inventory (modified abbreviated version)   1
  Ruff 2 and 7                                                 1
